Overdiagnosis in cancer - PubMed (original) (raw)
Review
. 2010 May 5;102(9):605-13.
doi: 10.1093/jnci/djq099. Epub 2010 Apr 22.
Affiliations
- PMID: 20413742
- DOI: 10.1093/jnci/djq099
Review
Overdiagnosis in cancer
H Gilbert Welch et al. J Natl Cancer Inst. 2010.
Abstract
This article summarizes the phenomenon of cancer overdiagnosis-the diagnosis of a "cancer" that would otherwise not go on to cause symptoms or death. We describe the two prerequisites for cancer overdiagnosis to occur: the existence of a silent disease reservoir and activities leading to its detection (particularly cancer screening). We estimated the magnitude of overdiagnosis from randomized trials: about 25% of mammographically detected breast cancers, 50% of chest x-ray and/or sputum-detected lung cancers, and 60% of prostate-specific antigen-detected prostate cancers. We also review data from observational studies and population-based cancer statistics suggesting overdiagnosis in computed tomography-detected lung cancer, neuroblastoma, thyroid cancer, melanoma, and kidney cancer. To address the problem, patients must be adequately informed of the nature and the magnitude of the trade-off involved with early cancer detection. Equally important, researchers need to work to develop better estimates of the magnitude of overdiagnosis and develop clinical strategies to help minimize it.
Comment in
- Solving the overdiagnosis dilemma.
Esserman L, Thompson I. Esserman L, et al. J Natl Cancer Inst. 2010 May 5;102(9):582-3. doi: 10.1093/jnci/djq119. Epub 2010 Apr 22. J Natl Cancer Inst. 2010. PMID: 20413743 No abstract available. - Re: Overdiagnosis in cancer.
Henson DE, Siddiqui H, Schwartz AM. Henson DE, et al. J Natl Cancer Inst. 2010 Dec 1;102(23):1809-10; author reply 1810-1. doi: 10.1093/jnci/djq410. Epub 2010 Oct 11. J Natl Cancer Inst. 2010. PMID: 20937990 No abstract available. - Less is more: not "going the distance" and why.
Harris R, Kinsinger LS. Harris R, et al. J Natl Cancer Inst. 2011 Dec 7;103(23):1726-8. doi: 10.1093/jnci/djr446. Epub 2011 Nov 9. J Natl Cancer Inst. 2011. PMID: 22076286 No abstract available.
Similar articles
- Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H. Draisma G, et al. J Natl Cancer Inst. 2009 Mar 18;101(6):374-83. doi: 10.1093/jnci/djp001. Epub 2009 Mar 10. J Natl Cancer Inst. 2009. PMID: 19276453 Free PMC article. - Solving the overdiagnosis dilemma.
Esserman L, Thompson I. Esserman L, et al. J Natl Cancer Inst. 2010 May 5;102(9):582-3. doi: 10.1093/jnci/djq119. Epub 2010 Apr 22. J Natl Cancer Inst. 2010. PMID: 20413743 No abstract available. - Early-stage prostate cancer, PSA screening rates decline.
Printz C. Printz C. Cancer. 2016 Mar 15;122(6):825. doi: 10.1002/cncr.29930. Cancer. 2016. PMID: 26938268 No abstract available. - Breast, prostate, and thyroid cancer screening tests and overdiagnosis.
Jung M. Jung M. Curr Probl Cancer. 2017 Jan-Feb;41(1):71-79. doi: 10.1016/j.currproblcancer.2016.11.006. Epub 2016 Dec 20. Curr Probl Cancer. 2017. PMID: 28104314 Review. - Cancer trends in the United States--a view from Europe.
Quinn MJ. Quinn MJ. J Natl Cancer Inst. 2003 Sep 3;95(17):1258-61. doi: 10.1093/jnci/djg063. J Natl Cancer Inst. 2003. PMID: 12953072 Review. No abstract available.
Cited by
- Temporal trends of thyroid cancer in China and globally from 1990 to 2021: an analysis of the global burden of Disease Study 2021.
Huang K, Huang X, Qian S, Cai Y, Wu F, Luo D. Huang K, et al. Sci Rep. 2024 Oct 26;14(1):25538. doi: 10.1038/s41598-024-77663-5. Sci Rep. 2024. PMID: 39462100 Free PMC article. - Prevalence of incidental prostate cancer: A systematic review of autopsy studies.
Bell KJ, Del Mar C, Wright G, Dickinson J, Glasziou P. Bell KJ, et al. Int J Cancer. 2015 Oct 1;137(7):1749-57. doi: 10.1002/ijc.29538. Epub 2015 Apr 21. Int J Cancer. 2015. PMID: 25821151 Free PMC article. Review. - Obligate and Potential Precursors of Melanoma.
Elder DE. Elder DE. J Natl Cancer Inst. 2022 Oct 6;114(10):1320-1322. doi: 10.1093/jnci/djac139. J Natl Cancer Inst. 2022. PMID: 36042556 Free PMC article. No abstract available. - Initial Longitudinal Outcomes of Risk-Stratified Men in Their Forties Screened for Prostate Cancer Following Implementation of a Baseline Prostate-Specific Antigen.
Michael ZD, Kotamarti S, Arcot R, Morris K, Shah A, Anderson J, Armstrong AJ, Gupta RT, Patierno S, Barrett NJ, George DJ, Preminger GM, Moul JW, Oeffinger KC, Shah K, Polascik TJ; Duke Cancer Institute Planning Committee for Prostate Cancer Screening. Michael ZD, et al. World J Mens Health. 2023 Jul;41(3):631-639. doi: 10.5534/wjmh.220068. Epub 2022 Aug 16. World J Mens Health. 2023. PMID: 36047079 Free PMC article. - Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies.
Gulati R, Feuer EJ, Etzioni R. Gulati R, et al. Am J Epidemiol. 2016 Jul 15;184(2):140-7. doi: 10.1093/aje/kwv342. Epub 2016 Jun 29. Am J Epidemiol. 2016. PMID: 27358266 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources